AACR 2026 Concludes in San Diego: Peptide Radioconjugates, Bicycles, and Macrocyclic Modalities Take Spotlight
The AACR Annual Meeting 2026 concluded April 22 in San Diego after six days featuring unprecedented peptide-oncology visibility. Macrocyclic peptide drug conjugate (PDC) pipelines across Circle Pharma, Bicycle Therapeutics, Oncopeptides, and SignaBlok drew regulatory and venture attention; peptide-targeting radioligand data from Perspective Therapeutics, Bicycle, and AlphaGen signaled maturation of the peptide-radioconjugate subcategory. AACR Advances sessions throughout the meeting featured targeted protein degradation and novel tumor-selective modalities, with peptide-based approaches competing directly with antibody drug conjugates in Phase 1/2 readouts.